Blueprint Medicines Corp (BPMC)
94.90
+3.51
(+3.84%)
USD |
NASDAQ |
May 01, 16:00
94.90
0.00 (0.00%)
After-Hours: 20:00
Blueprint Medicines Cash from Financing (Quarterly): 15.53M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 15.53M |
| September 30, 2023 | 98.40M |
| June 30, 2023 | 5.298M |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 2.491M |
| September 30, 2022 | 380.56M |
| June 30, 2022 | 177.50M |
| March 31, 2022 | 1.264M |
| December 31, 2021 | 17.93M |
| September 30, 2021 | 10.92M |
| June 30, 2021 | 14.85M |
| March 31, 2021 | 7.011M |
| December 31, 2020 | 220.09M |
| September 30, 2020 | 84.34M |
| June 30, 2020 | 3.175M |
| March 31, 2020 | 310.15M |
| December 31, 2019 | 1.834M |
| September 30, 2019 | 4.495M |
| June 30, 2019 | 332.30M |
| March 31, 2019 | 2.011M |
| Date | Value |
|---|---|
| December 31, 2018 | 0.764M |
| September 30, 2018 | 0.113M |
| June 30, 2018 | 0.515M |
| March 31, 2018 | 3.062M |
| December 31, 2017 | 327.85M |
| September 30, 2017 | 0.372M |
| June 30, 2017 | 216.14M |
| March 31, 2017 | -0.42M |
| December 31, 2016 | 134.63M |
| September 30, 2016 | -0.731M |
| June 30, 2016 | -0.518M |
| March 31, 2016 | -0.804M |
| December 31, 2015 | -0.343M |
| September 30, 2015 | -0.52M |
| June 30, 2015 | 154.63M |
| March 31, 2015 | -0.547M |
| December 31, 2014 | 54.60M |
| September 30, 2014 | 0.017M |
| June 30, 2014 | 1.749M |
| March 31, 2014 | 24.99M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
Mar 2023
380.56M
Maximum
Sep 2022
88.85M
Average
14.85M
Median
Jun 2021
Cash from Financing (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 39.23M |
| Apellis Pharmaceuticals Inc | -3.913M |
| Ionis Pharmaceuticals Inc | 40.72M |
| Madrigal Pharmaceuticals Inc | 479.92M |
| Sarepta Therapeutics Inc | 1.943M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -78.93M |
| Cash from Investing (Quarterly) | 78.77M |
| Free Cash Flow | -452.91M |
| Free Cash Flow Per Share (Quarterly) | -1.373 |
| Free Cash Flow to Equity (Quarterly) | -84.04M |
| Free Cash Flow to Firm (Quarterly) | -78.43M |
| Free Cash Flow Yield | -7.88% |